FDA opens rare-disease drug meetings to industry, patients, and experts—with transparency.

What it does

This bill creates a formal process for the FDA to hold externally-led, science-focused drug development meetings for rare diseases, run by the Reagan-Udall Foundation. These meetings bring together FDA staff, medical experts, drug companies, patient groups, and scientific organizations to discuss development challenges, align on trial designs and endpoints, and accelerate approval pathways. The bill requires at least four such meetings per year, public reporting of transcripts and consensus summaries, and FDA disclosure of how meeting input shaped drug approval decisions.

Why we flagged it

The bill's core mechanism is procedural—establishing a structured, externally-led forum for expert consensus on rare-disease drug development science. It is not a deregulation, liability shield, or subsidy; it is a transparency and coordination tool designed to reduce development friction.

What the text implies

• Industry representatives sit on the steering committee that selects meeting topics, creating potential for agenda-setting bias toward diseases with larger commercial markets or easier development pathways, even if unmet medical need is formally a criterion.
• The bill requires FDA to disclose how it incorporated meeting input into risk-benefit assessments, but does not require FDA to follow meeting consensus—creating a transparency obligation without a binding commitment, which may reduce industry incentive to participate if outcomes are unpredictable.
• The Reagan-Udall Foundation is a non-profit but receives substantial FDA funding and operates under FDA policy; external convening may create appearance of independence while actual agenda-setting remains influenced by FDA priorities and industry lobbying.
• Meetings focus on 'rare diseases' (defined by existing law as affecting <200,000 Americans), potentially excluding common diseases with unmet needs and larger patient populations from this accelerated development pathway.
• The $1M/year authorization is modest relative to FDA's $3B+ budget; underfunding could limit meeting frequency or quality, reducing the bill's practical impact on drug development timelines.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Patients with rare diseases gain faster access to treatments through structured expert consensus on development pathways, while transparency requirements (public meeting transcripts, FDA accountability statements) strengthen democratic oversight. The bill does not shield companies from liability or weaken safety standards—it streamlines the science-discussion phase before formal review.

Who stands to gain

• biopharmaceutical companies developing rare-disease treatments
• contract research organizations supporting rare-disease trials
• Reagan-Udall Foundation (receives convening contract and operational funding)

Named in the bill

FDA (Food and Drug Administration), Reagan-Udall Foundation for the Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH), rare disease patient organizations, biopharmaceutical industry, BIIB (Biogen, semantic affinity)

Where it stands

5 cosponsors: 3 Democrats, 2 Republicans.

• Feb 24, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 24, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 5 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $850,000 in lobbying spend. A filing names 7 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

Doris Matsui, the sponsor, reported $1,026,688 in PAC receipts in the 2026 cycle.

• Bridgebio Pharma, Inc. — $500,000 on 1 filing
• Ptc Therapeutics, Inc. — $170,000 on 1 filing
• Stealth Biotherapeutics Inc. — $120,000 on 1 filing
• Everylife Foundation for Rare Diseases — $60,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.